Paper39700441
Implementation of Universal Germline Genetic Testing Into Standard of Care for Patients With Prostate Cancer: The Time Is Now.
Shore N and 25 others. JCO Oncol Pract, 2025. Cited by 11 papers, by iCite.
Cite this record
ConductScience Library. Implementation of Universal Germline Genetic Testing Into Standard of Care for Patients With Prostate Cancer: The Time Is Now. Papers, record 39700441. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39700441
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Implementation of Universal Germline Genetic Testing Into Standard of Care for Patients With Prostate Cancer: The Time Is Now.
- PubMed
Topics6
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Genetic Testing | Major topic |
| Germ-Line Mutation | Major topic |
| Prostatic Neoplasms | Major topic |
| Standard of Care | Major topic |
| Humans | |
| Male |
Source PubMed
Grants2
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| P30 CA008748 | NCI NIH HHS | United States | P30CA008748 | PubMed and NIH | NIH RePORTER |
| R37 CA241486 | NCI NIH HHS | United States | R37CA241486 | PubMed and NIH | NIH RePORTER |
References96
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 35012874 | Helix: A Digital Tool to Address Provider Needs for Prostate Cancer Genetic Testing in Clinical Practice. | Clin Genitourin Cancer | 2022 | https://conductscience.org/library/papers/35012874 | PubMed |
| 2 | 30625039 | PROREPAIR-B: A Prospective Cohort Study of the Impact of Germline DNA Repair Mutations on the Outcomes of Patients With Metastatic Castration-Resistant Prostate Cancer. | J Clin Oncol | 2019 | https://conductscience.org/library/papers/30625039 | PubMed |
| 3 | 35930793 | Satisfaction With Clinician-Led Germline Genetic Counseling in Patients With Prostate Cancer. | J Urol | 2022 | https://conductscience.org/library/papers/35930793 | PubMed |
| 4 | 34711450 | Association of Inherited Mutations in DNA Repair Genes with Localized Prostate Cancer. | Eur Urol | 2022 | https://conductscience.org/library/papers/34711450 | PubMed |
| 5 | 37733366 | Germline Sequencing Analysis to Inform Clinical Gene Panel Testing for Aggressive Prostate Cancer. | JAMA Oncol | 2023 | https://conductscience.org/library/papers/37733366 | PubMed |
| 6 | 23569316 | Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. | J Clin Oncol | 2013 | https://conductscience.org/library/papers/23569316 | PubMed |
| 7 | 36600087 | Prostate cancer risk, screening and management in patients with germline BRCA1/2 mutations. | Nat Rev Urol | 2023 | https://conductscience.org/library/papers/36600087 | PubMed |
| 8 | 27989354 | Germline Mutations in ATM and BRCA1/2 Distinguish Risk for Lethal and Indolent Prostate Cancer and are Associated with Early Age at Death. | Eur Urol | 2017 | https://conductscience.org/library/papers/27989354 | PubMed |
| 9 | 26629066 | CHEK2 mutation and risk of prostate cancer: a systematic review and meta-analysis. | Int J Clin Exp Med | 2015 | https://conductscience.org/library/papers/26629066 | PubMed |
| 10 | 22236224 | Germline mutations in HOXB13 and prostate-cancer risk. | N Engl J Med | 2012 | https://conductscience.org/library/papers/22236224 | PubMed |
| 11 | 30730552 | Prevalence of Germline Variants in Prostate Cancer and Implications for Current Genetic Testing Guidelines. | JAMA Oncol | 2019 | https://conductscience.org/library/papers/30730552 | PubMed |
| 12 | 37276540 | Germline Genetic Testing After Cancer Diagnosis. | JAMA | 2023 | https://conductscience.org/library/papers/37276540 | PubMed |
| 13 | 37958398 | Phase II Trial Evaluating Olaparib Maintenance in Patients with Metastatic Castration-Resistant Prostate Cancer Responsive or Stabilized on Docetaxel Treatment: SOGUG-IMANOL Study. | Cancers (Basel) | 2023 | https://conductscience.org/library/papers/37958398 | PubMed |
| 14 | 33146377 | Racial and Ethnic Differences in Multigene Hereditary Cancer Panel Test Results for Women With Breast Cancer. | J Natl Cancer Inst | 2021 | https://conductscience.org/library/papers/33146377 | PubMed |
| 15 | 31629432 | Germline testing for prostate cancer prognosis: implications for active surveillance. | Can J Urol | 2019 | https://conductscience.org/library/papers/31629432 | PubMed |
| 16 | 36509074 | NCCN GuidelinesĀ® Insights: Prostate Cancer, Version 1.2023. | J Natl Compr Canc Netw | 2022 | https://conductscience.org/library/papers/36509074 | PubMed |
| 17 | 36103646 | Addition of Germline Testing to Tumor-Only Sequencing Improves Detection of Pathogenic Germline Variants in Men With Advanced Prostate Cancer. | JCO Precis Oncol | 2022 | https://conductscience.org/library/papers/36103646 | PubMed |
| 18 | 31337882 | Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the Prospective Lynch Syndrome Database. | Genet Med | 2020 | https://conductscience.org/library/papers/31337882 | PubMed |
| 19 | 34006922 | PALB2 mutations and prostate cancer risk and survival. | Br J Cancer | 2021 | https://conductscience.org/library/papers/34006922 | PubMed |
| 20 | 32986533 | Practical Considerations and Challenges for Germline Genetic Testing in Patients With Prostate Cancer: Recommendations From the Germline Genetics Working Group of the PCCTC. | JCO Oncol Pract | 2020 | https://conductscience.org/library/papers/32986533 | PubMed |
Cited by10
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 11 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42842178 | Bridging the implementation gap in hereditary cancer care for prostate cancer: a narrative review and Japanese environmental scan. | Int J Clin Oncol | 2026 | https://conductscience.org/library/papers/42842178 | PubMed |
| 42569313 | Recruitment strategies in the PROMISE Registry: Evaluating institutional outreach, direct-to-patient marketing, and community engagement approaches in a decentralized germline genetic registry. | Contemp Clin Trials Commun | 2026 | https://conductscience.org/library/papers/42569313 | PubMed |
| 42502690 | Identifying and characterizing the germinal genetic landscape of men with prostate cancer: A real-life, retrospective, multicenter study. | Genet Med Open | 2026 | https://conductscience.org/library/papers/42502690 | PubMed |
| 42422224 | Universal Germline Genetic Testing in a Precision Oncology and Rare Cancer Clinic: Implementation and Outcomes. | JCO Oncol Adv | 2026 | https://conductscience.org/library/papers/42422224 | PubMed |
| 41579216 | Delphi panel consensus on genetic testing for prostate cancer in Australia: Whom to test and how? | Fam Cancer | 2026 | https://conductscience.org/library/papers/41579216 | PubMed |
| 41568010 | Universal vs. ASCO guidelines-based germline genetic testing for newly diagnosed breast cancer patients in resource-restricted settings. | Oncol Rev | 2025 | https://conductscience.org/library/papers/41568010 | PubMed |
| 41330714 | Homologous recombination repair genetic testing variables and diagnostic paths for prostate cancer patients: a multicenter cohort study. | Oncologist | 2025 | https://conductscience.org/library/papers/41330714 | PubMed |
| 41294857 | Precision Oncology: Current Landscape, Emerging Trends, Challenges, and Future Perspectives. | Cells | 2025 | https://conductscience.org/library/papers/41294857 | PubMed |
| 41168197 | Whole genome sequencing-based analysis of genetic predisposition to adult glioblastoma. | NPJ Genom Med | 2025 | https://conductscience.org/library/papers/41168197 | PubMed |
| 40906325 | A phase 1b/2 study of intermittent talazoparib plus temozolomide in patients with metastatic castration-resistant prostate cancer and no mutations in DNA damage response genes. | Invest New Drugs | 2025 | https://conductscience.org/library/papers/40906325 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39700441
GET https://conductscience.org/api/papers/v1/39700441/authors?page=2